Novartis
NEWS
Novartis is not resting on the laurels of having the first-ever-approval for a CAR-T cancer drug, Kymriah.
Novartis announced they have expanded their collaboration with the Banner Alzheimer’s Institute to launch a new clinical trial in ALZ’s.
The scientist was among the nearly one dozen people injured on Oct. 31.
CryoPort handles the products for more than 172 of the more than 800 immunotherapy trials underway.
Days after plunking down $3.9B+ for AAA, Novartis may be looking to divest itself of its generic dermatology drug business.
Fresh off the heels of its CAR-T approval, Novartis expanded its oncological arsenal with a $3.9B acquisition of Advanced Accelerator Applications.
Big pharmas are having a good year so far in terms of FDA approvals.
The FDA based its decision on data from the COMBI-AD Phase III trial.
A look at how the gene therapy approvals may end up confusing payers, lawmakers, and the general public at a time when the industry desperately needs clarity.
JOBS
IN THE PRESS